Progression-free(PFS) and overall survival (OS) in treatment of BRAF mutation-positive metastatic melanoma: Bayesian network meta-analysis.

Mok Oh,Abdulaali Almutairi,Nimer Alsaid,Hani M. Babiker,Ali McBride,Ivo Abraham

Progression-free(PFS) and overall survival (OS) in treatment of BRAF mutation-positive metastatic melanoma: Bayesian network meta-analysis.

2018

Mok Oh
Abdulaali Almutairi
Nimer Alsaid
Hani M. Babiker
Ali McBride
Ivo Abraham

e21532Background: First-line treatment options for patients with BRAF-mutated metastatic melanoma include dacarbazine (DTIC), dabrafenib (DAB), dabrafenib + trametinib (DAB+TRA), vemurafenib (VEM),...

Keywords:

Melanoma
Pathology
Mutation
Medicine
Bayesian network
Trametinib
Dabrafenib
metastatic melanoma
Oncology
overall survival
Meta-analysis
Vemurafenib
Dacarbazine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations